PD-1 mAb (clone RMP1-14, BioXCell) was administered i.p. at 250 mg/kg daily on days 3–5 and 13–15. CD4 (clone GK1.5, BioXCell) and CD8 (clone YTS 169.4, BioXCell) depleting antibodies were administered i.p. at 200 mg/kg every other day starting 4 days prior to tumor implantation.
Cd4 clone gk1
Manufactured by BioXCell
The CD4 (clone GK1.5) is a laboratory reagent used for the detection and analysis of CD4+ T cells. It is a monoclonal antibody that specifically binds to the CD4 receptor expressed on the surface of T helper cells. This reagent can be used in flow cytometry and other immunological assays to identify and quantify CD4+ T cell populations.
Automatically generated - may contain errors
Lab products found in correlation
Cd8 clone yts 169, by BioXCell (3 mentions)
Nk1.1 clone pk136, by BioXCell (2 mentions)
Clone ebr2a, by Thermo Fisher Scientific (1 mentions)
Clone ltf 2, by BioXCell (1 mentions)
Anti mouse cd8α clone 2, by BioXCell (1 mentions)
Live dead fixable aqua dead cell kit, by Thermo Fisher Scientific (1 mentions)
Anti mouse cd28 clone 37.51, by BD (1 mentions)
Cd3e clone 145 2c11, by BD (1 mentions)
Rat igg2b, by BioXCell (1 mentions)
Mouse igg2a clone c1, by BioXCell (1 mentions)
8 protocols using cd4 clone gk1
1
Anti-PD-1 and CD4/CD8 Depletion
2
Immune Cell Depletion and Modulation
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
All antibodies blocking or neutralizing specific immune cell populations, cytokines or cytokine receptors and their corresponding isotype controls were acquired from BioXCell (West Lebanon): CD4 (clone GK1.5, #BE0003-1), CD8α (clone 2.43, #BE0061), NKG2D (clone HMG2D, #BE0111), NK1.1 (clone PK136, #BE0036), PD-1 (clone RMP1-14, #BE0146), IFNγ (clone R4-6A2, #BE0054), IFNAR1 (clone MAR1-5A3, #BE0241), IL-17A (clone 17F3, #BE0173). Antibodies in the amount of 0.2-0.4 mg/mouse were administered intraperitoneally once every 8 days or, in the case of anti-PD1, every 3 days for 3 times. For vaccinations experiments, ANXA1 neutralization was achieved with a specific antibody (clone 29, #610066 from BD Biosciences).
3
Colon Carcinoma Tumor Regression in Mice
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
8-week-old female
C57BL/6 mice were inoculated with MC38 colon carcinoma
cells subcutaneously as described above. Depletion antibodies were
administered starting 1 day before treatment, which was started when
tumors reached an average size of ∼100 mm3 and were
discontinued after treatment. CD4 (clone GK1.5, BioXCell, cat. no.
BE0003–1) and CD8α (Clone 2.43 BioXCell, cat. no. BE0061)
depletion antibodies and isotype control (BioXCell, cat. no. BE0086)
were administered at a dose of 400 μg every 3 days. CSF1R (clone
ASF98, BioXCell, cat. no. BE0213) depletion antibodies were administered
at a dose of 300 μg every other day. Treatment with p(Man-TLR7-PDS),
40 μg of TLR7 equiv in 30 μL of sterile PBS, occurred
every 3 days for a total of three doses. Tumor growth was recorded
as described above, and mice were euthanized when the tumor volume
exceeded 500 mm3 and/or based on humane end-point criteria.
C57BL/6 mice were inoculated with MC38 colon carcinoma
cells subcutaneously as described above. Depletion antibodies were
administered starting 1 day before treatment, which was started when
tumors reached an average size of ∼100 mm3 and were
discontinued after treatment. CD4 (clone GK1.5, BioXCell, cat. no.
BE0003–1) and CD8α (Clone 2.43 BioXCell, cat. no. BE0061)
depletion antibodies and isotype control (BioXCell, cat. no. BE0086)
were administered at a dose of 400 μg every 3 days. CSF1R (clone
ASF98, BioXCell, cat. no. BE0213) depletion antibodies were administered
at a dose of 300 μg every other day. Treatment with p(Man-TLR7-PDS),
40 μg of TLR7 equiv in 30 μL of sterile PBS, occurred
every 3 days for a total of three doses. Tumor growth was recorded
as described above, and mice were euthanized when the tumor volume
exceeded 500 mm3 and/or based on humane end-point criteria.
4
Monocyte, Macrophage, and T Cell Depletion
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
To deplete monocytes, wildtype C57BL/6 mice received I.V. injection of 200 μL of clodronate liposomes (or PBS control liposomes) 15–18 hours prior to infection [35 (link)]. Anti-CSF1R antibody (2 mg/mL, clone AFS98, eBioscience) was used to deplete bladder-resident macrophages. Animals received two I.V. injections, on consecutive days, of anti-CSF1R antibody or isotype control (clone eBR2a, eBioscience). We administered 400 μg/mouse on day 1 and 200 μg/mouse on day 2, to decrease the impact on circulating monocytes. To deplete T cells, 100 μg of CD4 (clone GK1.5, Bio X Cell) and 100 μg of CD8 (clone YTS 169.4, Bio X Cell) per mouse were injected together intraperitoneally 24 hours prior to primary infection. 200 μg of isotype control (clone LTF-2, Bio X Cell) per mouse was injected intraperitoneally. The depletion was repeated 5 days post-infection, and once a week to maintain the depletion until challenge infection.
5
Antibody-based Immune Modulation
6
Antibody Depletion of CD4+ T Cells
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
In some experiments, mice were treated with CD4 (clone GK1.5, BioXcell) depleting antibodies delivered intraperitoneally, starting on the day of Mtb infection and 7 days later (300 μg per mouse).
7
Depletion of Immune Cells in Teratoma Assay
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Mice were bled (as described in the humanized mice section) prior to the first injection of depleting antibodies. Mice were injected intraperitoneally with 250µg of one of the following depleting antibodies: mouse IgG2a (clone C1.18.4; BioXCell), rat IgG2b (BioXCell), CD8 (clone YTS169.4; BioXCell), CD4 (clone GK1.5; BioXCell), CD20 (clone SA271G2; BioLegend), or NK1.1 (clone PK136; BioXCell). Four days after injection, mice were bled to confirm depletion. hESCs were transplanted into these mice 5d after the initial depleting antibody injection. Depleting antibodies were administered weekly throughout the teratoma assay.
8
Depletion of CD4 and CD8 T cells in influenza challenge
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!